ALKERMES | ALKS - Cost Of Sales


ALKERMES reported $46.21M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Otsuka Holdings JPY 192.74B 11.78B Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025